RE
CHRS icon

Rydar Equities’s Coherus Oncology CHRS Stock Holding History

Rydar Equities’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.01K Buy
+1,000
New +$1.37K ﹤0.01% 417

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Rydar Equities's CHRS Position: Q3 2026 in Review

Rydar Equities opened a new position in Coherus Oncology (CHRS) in Q3 2026: 1,000 shares worth $1.01K. The stake represents ﹤0.01% of the portfolio and ranks #417 among its holdings.

7 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • Rydar Equities held 1,000 shares of Coherus Oncology worth $1.01K as of Q3 2026.
  • Coherus Oncology was a new Rydar Equities position in Q3 2026.
  • Coherus Oncology made up ﹤0.01% of Rydar Equities's portfolio in Q3 2026, its #417 holding.
  • 7 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.